Stock NMRA NEUMORA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Neumora Therapeutics, Inc.

Equities

NMRA

US6409791000

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-14 pm EDT 		5-day change 1st Jan Change
9.78 USD -1.71% Intraday chart for Neumora Therapeutics, Inc. -1.71% -42.64%
May. 14 Transcript : Neumora Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:00 AM
May. 14 Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression MT

Business Summary

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.

Number of employees: 120

Managers

Managers TitleAgeSince
Carol Suh FOU
 Founder 33 19-10-31
Henry Gosebruch CEO
 Chief Executive Officer 51 23-07-17
Paul Berns FOU
 Founder 57 19-10-31
Joshua Pinto DFI
 Director of Finance/CFO 38 21-05-31
Raj Manchanda CTO
 Chief Tech/Sci/R&D Officer 58 23-06-30
Nicholas Brandon CTO
 Chief Tech/Sci/R&D Officer 50 20-03-31
Robert Lenz CTO
 Chief Tech/Sci/R&D Officer - 23-10-09
Maryjo Chamberlain-Tharp PRN
 Corporate Officer/Principal 48 21-07-31
Amy Sullivan HRO
 Human Resources Officer - 20-12-31
Lori Houle PRN
 Corporate Officer/Principal 57 21-03-31

Members of the board

Members of the board TitleAgeSince
Paul Berns FOU
 Founder 57 19-10-31
May Kin Ho BRD
 Director/Board Member 71 21-03-31
Kristina Burow BRD
 Director/Board Member 50 19-12-31
Matthew Fust BRD
 Director/Board Member 59 20-11-30
Henry Gosebruch CEO
 Chief Executive Officer 51 23-07-17
Alaa Halawa BRD
 Director/Board Member 42 21-08-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 159,523,997 114,732,490 ( 71.92 %) 0 71.92 %

Shareholders

NameEquities%Valuation
AMGEN INC.
22.17 %
35,368,653 22.17 % 350 M $
ARCH Venture Partners LLC
20.02 %
31,932,138 20.02 % 316 M $
Biomatics Capital Management CO LLC
4.928 %
7,861,859 4.928 % 78 M $
SoftBank Capital Partners LLC
4.794 %
7,646,916 4.794 % 76 M $
Paul Berns
4.794 %
7,646,916 4.794 % 76 M $
Impresa Management LLC
3.526 %
5,624,353 3.526 % 56 M $
MIC Capital Management UK LLP
2.796 %
4,460,700 2.796 % 44 M $
T. Rowe Price Investment Management, Inc.
2.247 %
3,584,004 2.247 % 35 M $
ICONIQ Capital LLC
2.130 %
3,398,628 2.130 % 34 M $
Wellcome Trust Ltd. (Direct Investments)
2.074 %
3,309,123 2.074 % 33 M $

Company contact information

Neumora Therapeutics, Inc.

490 Arsenal Way Suite 200

02472, Watertown

+

http://www.neumoratx.com
address Neumora Therapeutics, Inc.(NMRA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
9.95 USD
Average target price
23.84 USD
Spread / Average Target
+139.61%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NEUMORA THERAPEUTICS, INC. Stock Neumora Therapeutics, Inc.
-42.64% 1.59B
MODERNA, INC. Stock Moderna, Inc.
+40.80% 55.66B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.05% 38.98B
LONZA GROUP AG Stock Lonza Group AG
+35.79% 38.8B
CELLTRION, INC. Stock Celltrion, Inc.
-8.98% 27.32B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.69% 26.29B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-16.21% 20.25B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+31.00% 12.76B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.51% 12.18B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-1.67% 12.12B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NMRA Stock
  4. Company Neumora Therapeutics, Inc.